Intensity Therapeutics (INTS) Director Thomas Dubin Receives Award

What Happened

• Thomas Dubin, a director of Intensity Therapeutics, received a derivative equity award for 5,500 shares (reported as acquired at $0.00) on July 16, 2026. The reported dollar value is $0 because no cash was paid for the award; it is listed as a grant/award rather than a market purchase or sale.

Key Details

• Transaction date: July 16, 2026; Form 4 filed: July 20, 2026 (filed within the required reporting window).
• Transaction type/code: A — grant/award (derivative).
• Amount: 5,500 shares granted at $0.00 (reported value $0).
• Shares owned after transaction: not specified in the provided filing.
• Footnote: Award vests in four equal annual installments beginning July 16, 2026, subject to continued service.
• No indication of exercise, sale, tax withholding, or 10b5-1 plan in the reported transaction.

Context

• This is a compensation grant to a director and not an open-market purchase or sale; such awards are commonly used to align management/directors with shareholders but do not by themselves indicate immediate buying or selling of stock. The award vests over time, so economic benefit depends on continued service and future company performance.